Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4855063 | 0.90 | TP53 (0.44) | LMNATP53GAATRIM24CYP11B1 | |
| SCHEMBL4862751 | 0.87 | TP53 (0.43) | LMNATP53GAATRIM24CYP11B1 | |
| SCHEMBL4861189 | 0.81 | TRIM24 (0.43) | LMNATRIM24CYP11B1CYP11B2SMN1; SMN2 | |
| SCHEMBL4854074 | 0.81 | CYP11B1 (0.41) | LMNATRIM24CYP11B1CYP11B2SMN1; SMN2 | |
| SCHEMBL4857554 | 0.80 | LMNA (0.43) | LMNATP53MAPTSMN1; SMN2 | |
| SCHEMBL4858788 | 0.80 | CYP11B1 (0.42) | LMNAGAATRIM24CYP11B1CYP11B2 | |
| SCHEMBL4861394 | 0.79 | NOTUM (0.39) | CYP11B1CYP11B2 | |
| SCHEMBL4861577 | 0.77 | TP53 (0.46) | LMNATP53GAATRIM24CYP11B1 | |
| SCHEMBL4851828 | 0.75 | TRIM24 (0.36) | LMNATRIM24CYP11B1CYP11B2 | |
| SCHEMBL4857483 | 0.75 | HSD17B3 (0.39) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| US-7138533-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-21 | — | — | US | disclosed |
| US-7132547-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-07 | — | — | US | disclosed |
| US-20060211675-A1 | Preventives/remedies for urinary disturbance | ISHIHARA YUJI | 2006-09-21 | — | — | US | disclosed |
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-03-23 | — | — | US | disclosed |
| US-20050197362-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-09-08 | — | — | US | disclosed |
| EP-1466625-A1 | PREVENTIVES/REMEDIES FOR URINARY DISTURBANCE | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, CHRM1 | LMNA 1921/4885TP53 4560/4885GAA 372/4885 |
| US-20050197362-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, CHRM1 | LMNA 1921/4885TP53 4560/4885GAA 372/4885 |
| US-20060211675-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, ACE | LMNA 2218/4885TP53 4160/4885GAA 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.